One in Five New Dermatology Drugs Were First in Class Over the Past Decade
By Lori Solomon HealthDay Reporter
Samir Kamat, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues characterized the frequency and degree of innovation of new dermatologic drugs (topical or systemic) approved by the U.S. Food and Drug Administration from 2012 to 2022.
The researchers identified 52 new drug applications and 26 supplemental new indications approved by the FDA. Among the new drugs, 21 percent were categorized as first in class and 25 percent as first in indication. Health technology assessment organizations in Germany, Canada, or France rated 39 percent of new drugs as clinically useful or having high added therapeutic benefit and 30 percent of the supplemental new indications as clinically useful or having high added therapeutic benefit.
"This study suggests that innovative dermatologic drug development may have increased over the past decade, offering promise for patients with skin disease," the authors write. "However, these findings also highlight opportunities to develop more truly innovative dermatologic agents, particularly for diseases with unmet therapeutic need."
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Benzene Exposure Results From Benzoyl Peroxide Drug Product Use
FRIDAY, Oct. 11, 2024 -- Potential benzene exposure occurs as a result of benzoyl peroxide (BPO) drug product use, according to a study published online Oct. 7 in the Journal of...
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
FRIDAY, Oct. 4, 2024 -- For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.